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Purpose: Anophthalmia and microphthalmia (A/M) are rare congenital ocular malformations presenting with the absence
of eye components or small eyes with or without structural abnormalities. A/M can be isolated or syndromic. The
stimulated by retinoic acid gene 6 (STRA6) and Sloan-Kettering viral oncogene homolog (SKI) genes are involved in
vitamin A metabolism, and are implicated with A/M developmental abnormalities in human and animal studies. Vitamin
A metabolism is vital to normal eye development and growth. This study explores the association of these genes in a
cohort of subjects with A/M.
Methods: STRA6 and SKI were screened for sequence variants by direct sequencing of genomic DNA samples from 18
affected subjects with A/M. The DNA samples of 4 external, unrelated controls were initially screened. Eighty-nine
additional unrelated controls were screened to confirm that any sequence variants found in the affected subject DNA
samples were related to the phenotype. Coding regions, intron-exon boundaries, and untranslated regions were sequenced
by standard techniques. Derived DNA sequences were compared to known reference sequences from public genomic
databases.
Results: For STRA6, a novel coding non-synonymous sequence variant was found in one subject, resulting in an amino
acid change from glycine to glutamic acid in residue 217. One novel nonsense sequence variant found in the same subject
changed the STRA6 amino acid residue 592 from cytosine to thymine resulting in a premature stop codon. For SKI, a
known coding non-synonymous sequence variant (rs28384811) was found in 3 subject DNA samples and 11/89 control
DNA samples. Four novel coding-synonymous sequence variants were observed in SKI.
Conclusions: The STRA6 sequence variants reported in this study could play a role in the pathogenesis of A/M by structural
changes to the STRA6 protein. We can attribute 4% A/M incidence in this cohort to these sequence variants. Although no
SKI sequence variants were found in this cohort, SKI should not be ruled out as a candidate gene for A/M due to the small
cohort size.
Anophthalmia  and  microphthalmia  (A/M)  are  rare
congenital ocular malformations presenting with the absence
of  eye  components  (anophthalmia)  or  small  eyes  with  or
without structural abnormalities (microphthalmia). A/M has
a prevalence of approximately 30 per 100,000 population
[1-3], or 70 incidents per 480,000 live births in the United
States [4]. A/M may be isolated or syndromic with varied
patterns of inheritance. Many genetic loci are associated with
either isolated or syndromic A/M. To date, there are 3 genetic
loci  identified  for  isolated  A/M;  MCOP1  (14q32;  OMIM
251600),  MCOP2  (14q24.3;  OMIM  610093),  MCOP3
(18q21.3;  OMIM  601881).  In  addition,  there  are  10  loci
identified for syndromic A/M; MCOPS1 (Xq27–28; OMIM
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309800),  MCOPS2  (Xp11.4;  OMIM  300166),  MCOPS3
(3q26.3-q27; OMIM 206900), MCOPS4 (Xq27–28; OMIM
301590), MCOPS5 (14q21–22; OMIM 610125), MCOPS6
(14q22–23;  OMIM  607932),  MCOPS7  (Xp22;  OMIM
309801)  MCOPS8  (6q21;  OMIM  601349),  MCOPS9
(15q24.1; OMIM 601186), and MCOPS10 (OMIM 601186).
There are other syndromes or genes that have been associated
with  A/M;  CHARGE  Syndrome  (8q12.1,  7q21.1;  OMIM
214800), Frasier Syndrome (13q13.3, 4q21; OMIM 219000),
and the paired box gene 6 (PAX6; 11p13; OMIM 607108).
The large number of loci associated with A/M reflects the
heterogeneity of this ocular malformation.
Current research in determining the genetic etiology of
A/M has primarily focused on known gene mutations in SRY
- (sex determining region Y)-box 2 (SOX2; OMIM 184429),
paired  box  gene  6  (PAX6;  OMIM  607108),  orthodenticle
homeobox  2  (OTX2;  OMIM  600037),  C.  elegans  ceh-10
homeo  domain  containing  homolog  (CHX10;  OMIM
142993),  and  retina  and  anterior  neural  fold  homeobox
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Khanh-Nhat Tran-Viet,1 Terri L. Young1,2(RAX;  OMIM  601881).  SOX2,  OTX2,  and  PAX6  are  all
necessary for ocular development [5]. OTX2,PAX6, and SOX2
are also involved in vitamin A metabolism either directly or
through complex gene-gene interactions [6-8]. The present
cohort studied was screened for SOX2 and CHX10 sequence
variants in a previous study [9], and no pathogenic SOX2 or
CHX10 mutations were found.
Although various mutations and deletions of the genes
listed above are implicated in many cases of A/M, these genes
do not account for all cases of A/M. Recently, homozygous
mutations in the stimulated by retinoic acid gene 6 (MCOPS9;
STRA6) [10,11] were identified in families with Matthew-
Wood  syndrome,  an  A/M  phenotype  associated  with
pulmonary  hypoplasia  and  cardiovascular  malformations
[12]. STRA6 maps to chromosome 15q.24.1 and is a 20 xon
gene encoding a protein of 667 amino acids (Figure 1). STRA6
encodes for a trans-membrane receptor for the retinol binding
protein (RBP) which enhances cellular uptake of vitamin A
or retinol [13]. RBP is necessary for the transport of retinol to
specific sites in the eye, such as the retinal pigment epithelium
layer and retinal vasculature [13]. Following the uptake into
the cell, retinol is oxidized to retinal which is in turn oxidized
to retinoic acid (RA) [14]. Vitamin A and its derivatives are
important substrates for proper ocular development and other
cellular functions [14-16].
In a recent report, C57BL/6J mice lacking the Sloan-
Kettering viral oncogene homolog (Ski) gene had a complex
ocular phenotype that included microphthalmia, hyperplastic
hyaloid  vasculature,  and  severe  abnormalities  of  the  iris
ranging from aniridia to iris coloboma [17,18]. SKI maps to
chromosome 1p36.3 and is a 7 xon gene encoding a protein
of 728 amino acids (Figure 2). The SKI gene primary domain
interacts  with  the  small  mothers  against  decapentaplegic
proteins (SMAD) to repress the transcription of transforming
growth  factor-beta  (TGF-β)  genes  [19].  The  TGF-β  gene
family is a major regulator of cellular functions such as cell
proliferation, apoptosis, specification, development fate, and
ocular growth [20,21]. SKI is also an activator of MITF, a gene
implicated in microphthalmia [19]. Nuclear SKI binds to the
active retinoic acid receptor (RAR) complex and recruits co-
repressors  inhibiting  transcription  mediated  by  the  active
RAR  complex  [22].  SKI  inhibits  RAR  signaling  through
different pathways including the brain all-trans-retinoic acid
signaling, TGF-β, and bone morphogenetic protein pathways
[22,23].
STRA6 and SKI are candidate genes associated with the
A/M phenotype and are involved in vitamin A metabolism and
RA  signaling.  We  hypothesized  that  sequence  variants  in
either STRA6 or SKI may give rise to the A/M phenotype. In
this study, a cohort of 18 patients with A/M was screened for
sequence variants in STRA6 and SKI.
METHODS
Subjects:  Informed  consent  was  obtained  from  all
participants.  The  study  followed  the  principles  of  the
Declaration of Helsinki, and was approved by the Institutional
Review  Board  at  the  Duke  University  Medical  Center.
Eighteen A/M probands and 4 external control subjects (all
unrelated) were initially screened to identify known and novel
sequence variants. Subject demographics are listed in Table
1.  Genomic  DNA  was  extracted  via  venous  blood  using
AutoPure LS® DNA Extractor and PUREGENE™ reagents
(Gentra Systems Inc., Minneapolis, MN). Novel coding non-
synonymous and nonsense sequence variants identified in a
proband  were  further  tested  in  89  external  control  DNA
samples.
Polymerase  chain  reaction  (PCR)  and  DNA  sequencing:
Seventeen and twelve primer sets were designed to amplify
the 19 exons of STRA6 and the 7 exons of SKI, respectively.
Each amplicon extended 50–100 base pairs beyond the intron-
exon boundary and the 5′ and 3′ untranslated regions (UTRs)
of the genes. Amplification of the 5′ genomic sequence of SKI
exon 1 using multiple primer sets was unsuccessful due to high
GC content. PCRs run using either a normal reaction or a 1M
Betaine  (Sigma-Aldrich,  Saint  Louis,  MO)  reaction  were
performed on genomic DNA from the 18 A/M patients and 4
Figure 1. The STRA6 gene structure showing the intron-exon layout. The STRA6 gene comprises 20 exons, with several alternate first exons,
coding for a protein 667 amino acids in length. Generated from the Gene Structure Display Server.
Figure 2. SKI gene structure showing the intron-exon layout of the 7-exon gene. The SKI gene comprises 7 exons which code for a 728 amino
acid long protein. Generated from the Gene Structure Display Server.
Molecular Vision 2008; 14:2458-2465 <http://www.molvis.org/molvis/v14/a283> © 2008 Molecular Vision
2459T
A
B
L
E
 
1
.
 
S
U
B
J
E
C
T
 
D
E
M
O
G
R
A
P
H
I
C
S
 
A
N
D
 
C
L
I
N
I
C
A
L
 
D
E
S
C
R
I
P
T
I
O
N
S
.
S
u
b
j
e
c
t
I
D
A
g
e
 
a
t
a
s
c
e
r
t
a
i
n
m
e
n
t
G
e
n
d
e
r
R
a
c
e
O
c
u
l
a
r
 
p
h
e
n
o
t
y
p
e
S
y
s
t
e
m
i
c
 
f
i
n
d
i
n
g
s
F
a
m
i
l
y
 
h
i
s
t
o
r
y
1
3
y
r
s
 
2
 
m
o
n
t
h
s
M
C
a
u
c
a
s
i
a
n
B
i
l
a
t
e
r
a
l
 
m
i
c
r
o
p
h
t
h
a
l
m
i
a
C
l
e
f
t
 
l
i
p
 
a
n
d
 
p
a
l
a
t
e
D
e
v
e
l
o
p
m
e
n
t
a
l
 
d
e
l
a
y
A
d
o
p
t
e
d
2
3
y
r
s
M
C
a
u
c
a
s
i
a
n
A
n
o
p
h
t
h
a
l
m
i
a
/
M
i
c
r
o
p
h
t
h
a
l
m
i
a
N
o
n
e
B
r
o
t
h
e
r
 
w
i
t
h
 
A
/
M
3
7
 
m
o
n
t
h
s
F
C
a
u
c
a
s
i
a
n
U
n
i
l
a
t
e
r
a
l
 
m
i
c
r
o
p
h
t
h
a
l
m
i
a
N
o
n
e
N
o
n
e
4
1
1
 
d
a
y
s
F
C
a
u
c
a
s
i
a
n
B
i
l
a
t
e
r
a
l
 
m
i
c
r
o
p
h
t
h
a
l
m
i
a
4
6
,
 
X
X
,
 
d
e
r
 
(
4
)
 
t
 
(
2
,
4
)
(
q
3
1
.
1
;
q
3
3
)
 
C
h
o
a
n
a
l
 
a
t
r
e
s
i
a
,
c
o
n
g
e
n
i
t
a
l
 
h
e
a
r
t
 
d
i
s
e
a
s
e
,
 
l
u
n
g
h
y
p
o
p
l
a
s
i
a
,
 
a
n
d
 
d
e
v
e
l
o
p
m
e
n
t
a
l
d
e
l
a
y
.
N
o
n
e
5
2
8
 
y
e
a
r
s
 
1
 
m
o
n
t
h
s
M
C
a
u
c
a
s
i
a
n
U
n
i
l
a
t
e
r
a
l
 
m
i
c
r
o
p
h
t
h
a
l
m
i
a
N
o
n
e
N
o
n
e
6
7
 
m
o
n
t
h
s
M
A
f
r
i
c
a
n
 
A
m
e
r
i
c
a
n
B
i
l
a
t
e
r
a
l
 
m
i
c
r
o
p
h
t
h
a
l
m
i
a
N
o
n
e
N
o
n
e
7
5
 
y
e
a
r
s
 
6
 
m
o
n
t
h
s
F
C
a
u
c
a
s
i
a
n
B
i
l
a
t
e
r
a
l
 
m
i
c
r
o
p
h
t
h
a
l
m
i
a
N
o
n
e
N
o
n
e
8
1
 
y
e
a
r
 
4
 
m
o
n
t
h
s
M
C
a
u
c
a
s
i
a
n
M
i
c
r
o
p
h
t
h
a
l
m
i
a
 
O
S
N
o
n
e
N
o
n
e
9
6
 
y
e
a
r
s
 
5
 
m
o
n
t
h
s
M
C
a
u
c
a
s
i
a
n
M
i
c
r
o
p
h
t
h
a
l
m
i
a
 
O
D
N
o
n
e
N
o
n
e
1
0
1
 
y
e
a
r
 
7
 
m
o
n
t
h
s
F
C
a
u
c
a
s
i
a
n
M
i
c
r
o
p
h
t
h
a
l
m
i
a
 
O
S
N
o
n
e
N
o
n
e
1
1
6
 
y
e
a
r
s
 
9
 
m
o
n
t
h
s
F
C
a
u
c
a
s
i
a
n
B
i
l
a
t
e
r
a
l
 
a
n
o
p
h
t
h
a
l
m
i
a
D
u
p
l
i
c
a
t
e
d
 
k
i
d
n
e
y
 
c
o
l
l
e
c
t
i
n
g
s
y
s
t
e
m
N
o
n
e
1
2
3
 
y
e
a
r
s
 
5
 
m
o
n
t
h
s
M
C
a
u
c
a
s
i
a
n
B
i
l
a
t
e
r
a
l
 
m
i
c
r
o
p
h
t
h
a
l
m
i
a
C
l
e
f
t
 
l
i
p
 
a
n
d
 
p
a
l
a
t
e
A
d
o
p
t
e
d
1
3
6
 
y
e
a
r
s
 
3
 
m
o
n
t
h
s
M
C
a
u
c
a
s
i
a
n
B
i
l
a
t
e
r
a
l
 
m
i
c
r
o
p
h
t
h
a
l
m
i
a
S
c
i
m
i
t
a
r
 
s
y
n
d
r
o
m
e
(
a
n
o
m
a
l
o
u
s
 
p
u
l
m
o
n
a
r
y
 
v
e
n
o
u
s
s
y
s
t
e
m
)
N
o
n
e
1
4
1
5
 
y
e
a
r
s
 
1
 
m
o
n
t
h
s
F
A
s
i
a
n
B
i
l
a
t
e
r
a
l
 
a
n
o
p
h
t
h
a
l
m
i
a
V
e
n
t
r
i
c
u
l
a
r
-
s
e
p
t
a
l
 
d
e
f
e
c
t
.
F
u
s
e
d
 
t
o
o
t
h
.
N
o
n
e
1
5
2
 
y
e
a
r
s
 
6
 
m
o
n
t
h
s
F
C
a
u
c
a
s
i
a
n
B
i
l
a
t
e
r
a
l
 
m
i
c
r
o
p
h
t
h
a
l
m
i
a
H
y
p
o
t
o
n
i
a
,
 
t
r
e
m
o
r
s
,
 
l
a
x
l
i
g
a
m
e
n
t
s
M
o
t
h
e
r
 
w
i
t
h
 
p
o
l
a
r
c
a
t
a
r
a
c
t
s
1
6
4
 
m
o
n
t
h
s
F
H
i
s
p
a
n
i
c
M
i
c
r
o
p
h
t
h
a
l
m
i
a
 
O
D
 
A
n
o
p
h
t
h
a
l
m
i
a
O
S
N
o
n
e
N
o
n
e
1
7
2
 
y
e
a
r
s
M
C
a
u
c
a
s
i
a
n
B
i
l
a
t
e
r
a
l
 
a
n
o
p
h
t
h
a
l
m
i
a
N
o
n
e
N
o
n
e
1
8
4
 
y
e
a
r
s
 
2
 
m
o
n
t
h
s
M
C
a
u
c
a
s
i
a
n
B
i
l
a
t
e
r
a
l
 
a
n
o
p
h
t
h
a
l
m
i
a
N
o
n
e
N
o
n
e
A
l
l
 
c
a
s
e
s
 
w
e
r
e
 
p
o
s
t
-
n
a
t
a
l
,
 
a
n
d
 
t
h
e
r
e
 
w
a
s
 
n
o
 
k
n
o
w
n
 
p
a
r
e
n
t
a
l
 
c
o
n
s
a
n
g
u
i
n
i
t
y
.
 
O
D
=
R
i
g
h
t
 
e
y
e
,
 
O
S
=
L
e
f
t
 
e
y
e
.
Molecular Vision 2008; 14:2458-2465 <http://www.molvis.org/molvis/v14/a283> © 2008 Molecular Vision
2460external  controls  using  Platinum®  Taq  DNA  polymerase
(Invitrogen  Corporation,  Carlsbad,  CA).  Amplicons  were
visualized  after  electrophoresis  on  a  2%  agarose  gel  and
purified  using  Quickstep™  2  SOPE™  Resin  (Edge
BioSystems, Gaithersburg, MD). Sequencing reactions were
performed using BigDye™ Terminator v1.3 and run on an
ABI3730 Sequencer (Applied Biosystems, Inc., Foster City,
CA). Sequences were trimmed for quality and aligned with
the  corresponding  reference  sequences  (i.e.,  STRA6
[NM_022369]  and  SKI  [NM_003036])  using  the
Sequencher™ program (Gene Codes, Ann Arbor, MI). DNA
sequences  were  analyzed  and  compared  to  determine
sequence variants.
RESULTS
Twenty-two sequence variants (1 nonsense, 2 missense, 1
silent, 6 UTR, 10 intronic, 1 intronic deletion, and 1 intronic
insertion) were identified in STRA6. Among them, 7 were
novel, including 1 missense and 1 nonsense sequence variant.
The novel missense sequence variant (Figure 3) in exon 8 of
STRA6  was  noted  in  subject  11.  This  guanine  to  adenine
sequence  variant  changes  amino  acid  residue  217  from
glycine to glutamic acid (Table 2). A novel nonsense sequence
variant (Figure 3) in exon 18 was also noted for the same
subject (Table 2). The nonsense sequence variant changes
amino acid residue 592 from cytosine to thymine resulting in
a  premature  stop  codon.  Neither  sequence  variant  was
detected  in  89  external  control  DNA  samples.  No  other
sequence variants were associated with the disease status. All
non-coding STRA6 sequence variants observed are reported in
Appendix 1.
Figure  3.  Chromatograms  showing  STRA6  sequence  variants  in
subject 11. A and C display the novel missense sequence variant in
subject 11 in exon 8. This base pair sequence change of guanine to
adenine causes an amino acid change from glycine to glutamic acid
at residue 217. B and D display the novel nonsense sequence variant
in subject 11 in exon 18. This sequence variant changes the glutamine
amino acid residue at position 592 and produces a premature stop
codon.
For  SKI,  20  sequence  variants  were  identified;  1
missense, 5 silent, 9 intronic, 4 UTR, and 1 intronic deletion.
Thirteen of the 20 sequence variants found in SKI were novel.
A  known  coding  non-synonymous  sequence  variant,
rs28384811, was found in 3 affected subject DNA samples
(Table 3). This sequence variant changes amino acid residue
62 from alanine to glycine. However, this sequence variant
was also found in 11 out of 89 control DNA samples screened.
No other SKI sequence variants were found to be significant.
All non-coding SKI sequence variants observed are reported
in Appendix 2.
DISCUSSION
The  developmental  eye  disorders  anophthalmia  and
microphthalmia  may  involve  several  genes.  Identifying
causative genes will not only help improve understanding of
the disease process, it will also provide insight into ocular
growth and development of the eye in general. In this study,
we screened the candidate genes SKI and STRA6 in an A/M
cohort. Neither gene has been screened in a relatively non-
syndromic  cohort  of  A/M  patients  to  date.  We  report  1
nonsense  and  1  missense  sequence  variant  in  1  affected
subject (#11) in STRA6. These sequence variants were not
seen in 89 external control samples. Subject 11 is a Caucasian
female who was 6 years and 9 months old at the time of
ascertainment. There was no reported parental consanguinity.
The subject had bilateral microphthalmia and a duplicated
Figure  4.  Diagram  of  the  STRA6  protein  structure  showing
transmembrane regions, and intracellular and extracellular domains.
(Figure modified from Kawaguchi et al. [24], provided with the
author’s permission). Underlined sequence variants were found in
this study. The missense sequence variant at amino acid 217 changes
a hydrophobic glycine residue to a hydrophilic glutamic acid residue
located  in  a  hydrophobic  transmembrane  region.  The  nonsense
sequence variant at amino acid 592 causes a premature stop codon
on  the  COOH-terminus  end  of  the  STRA6  protein.  Previously
discovered sequence variants marked with asterisks are involved in
human  disease.  Other  sequence  variants  are  missense  mutations
annotated in the GenBank database, and are not currently known to
be associated with human disease.
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2461kidney collecting system as the only structural abnormalities
noted.  Subject  11  did  not  have  the  cardinal  features  of
Mathew-Wood Syndrome (MCOPS9), such as cardiopathy,
lung hypoplasia, and diaphragmatic hernia. We believe that
the A/M of subject 11 is non-syndromic, and that the STRA6
sequence  variants  reported  may  be  associated  with  this
phenotype.
The novel nonsense sequence variant in STRA6 changes
the glutamine residue at position 592 to produce a premature
stop codon. This stop codon cleaves the predicted COOH-
terminal domain of the protein. This highly conserved long
COOH-terminal domain is located intracellularly (Figure 4),
and is speculatively involved in vitamin A uptake [24]. Thus,
the cellular uptake of vitamin A may be affected by a truncated
STRA6 protein in the phenotype involved. Normal STRA6
function is critical for vitamin A uptake into cells, especially
during  embryonic  development  [25].  Little  or  no  STRA6
function leads to severe phenotypes including ocular defects
[10,11]. There are 2 known missense mutations in the COOH-
terminal domain associated with human anophthalmia (Figure
4) [10]. These 2 known mutations disrupt the normal function
of the C-terminal domain of the STRA6 protein, so it follows
that premature termination of the COOH-terminal domain
would also have a profound effect on the function of STRA6.
TABLE 2. SEQUENCE VARIANTS IN STRA6 DETERMINED BY DIRECT SEQUENCING.
Patient ID Exon 5 Exon 8 Exon 17 Exon 18
rs11857410 Novel rs736118 Novel
Coding
synonymous
Coding non-
synonymous
Coding non-
synonymous
Nonsense-stop
codon
1
2  
3 c.[331C>T ]
+[331C>T ], p.L111L
  c.[1581G>A]+[=], p.
[527M>I]+[=]
4  
5 c.[331C>T ] +[=],
p.L111L
 
6  
7   c.[1581G>A]+[=], p.
[527M>I]+[=]
8 c.[331C>T ]
+[331C>T ], p.L111L
 
9  
10 c.[331C>T ] +[=],
p.L111L
 
11   *c.[650G>A]+[=], p.
[217G>E]+[=]
  *c.[1774C>T]+[=], p.
[592Q>X]+[=]
12     c.[1581G>A]+[=], p.
[527M>I]+[=]
13     c.[1581G>A]+[=], p.
[527M>I]+[=]
14     c.[1581G>A]+[=], p.
[527M>I]+[=]
15
16
17 c.[331C>T ] +[=],
p.L111L
18
Control 1 c.[331C>T ] +[=],
p.L111L
Control 2 c.[331C>T ] +[=],
p.L111L
Control 3
Control 4 c.[331C>T ] +[=],
p.L111L
  c.[1581G>A]+[=], p.
[527M>I]+[=]
The 2 STRA6   sequence variants following affection status are marked with asterisks, the novel exon 8 coding non-synonymous
and the novel exon 18 nonsense sequence variants. These sequence variants were not detected in 89 control samples.
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2462The missense sequence variant observed in subject 11
alters amino acid 217 from a hydrophobic glycine residue to
a  hydrophilic  glutamic  acid  residue.  This  polarity  change
occurs in a highly conserved and hydrophobic transmembrane
region, the 5th predicted in the STRA6 protein (Figure 4)
[24].  This  is  likely  to  have  effects  on  protein  folding.
Computational analysis by the PolyPhen web tool predicted
the amino acid change from glycine to glutamic acid to be
possibly  damaging,  citing  an  improper  substitution  in  a
transmembrane region. A similar change was observed by
Kawaguchi et al. [25] in the STRA6 transmembrane region 6
(valine to glutamic acid) resulting in a severe reduction of
vitamin A uptake. We speculate that such disrupted vitamin
A metabolism, especially during development, is involved in
the A/M phenotype. Viable cell lines were not available for
subject 11 to confirm the nonsense and missense sequence
variants at the mRNA level. Parental DNA for subject 11 was
also  unavailable  to  determine  the  origin  of  these  two
potentially pathogenic variants.
SKI is also involved in the RA pathway, however unlike
STRA6 no SKI sequence variants segregated with affection
status. The known missense sequence variant (rs38284811)
found in 3 affected individuals changes amino acid residue 62
from alanine to glycine. This sequence variant may not be
responsible for the A/M phenotype, as it was also found in 11
out of 89 external controls screened. SKI should not be ruled
out as a candidate gene for A/M, as the cases studied may not
cover the entire A/M phenotype spectrum.
The  limitation  of  this  study  is  the  small  cohort  size
screened. The small cohort size and diverse nature of the
disease phenotypes studied in this cohort make it difficult to
extrapolate  the  incidence  rate  of  STRA6  mutations  in  the
general A/M population. However, it is difficult to collect
large, homogenous sample sets of isolated A/M patients. In
addition, different A/M populations need to be screened to
better ascertain the percentage of A/M cases due to mutations
in STRA6. Continued recruitment of A/M patients is necessary
for future genetic screenings.
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Patient ID Exon 1 Exon 1 Exon 4 Exon 4 Exon 5 Exon 6
rs28384811 Novel Novel Novel Novel Novel
Coding non-
synonymous
Coding synonymous      Coding
synonymous
Coding
synonymous
Coding
synonymous
Coding
synonymous
1
2
3
4
5         c.[1527C>T] +[=],
p.A509A
6
7
8
9 *c.[185C>G] +[=], p.
[62A>G]+[=]
c.[98C>G] +[=],
p.G33G
10 *c.[185C>G] +[185C>G], p.
[62A>G] +[62A>G]
11 *c.[185C>G] +[185C>G], p.
[62A>G] +[62A>G]
c.[98C>G]
+[98C>G], p.G33G
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14     c.[1440G>A] +[=],
p.S480S
15       c.[1446G>A] +[=],
p.A482A
16
17
18
Control 1           c.[1974C>T] +[=],
p.R658R
Control 2
Control 3
Control 4
The coding non-synonymous sequence variant (rs28384811) marked with an asterisk was also detected in 11 out of 89 control
DNA samples.
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2464Appendix 1: Intronic and untranslated region sequence variants found in
STRA6.
All non-coding sequence variants observed for STRA6 are
reported in this table. The novel 5 base pair insertion found
5′upstream of one of the alternate exons was found in 5/89
controls.  ‘-  -‘  denotes  lack  of  sequence  data  for  that
corresponding sample. To access the data, click or select the
words “Appendix 1.” This will initiate the download of a
compressed (pdf) archive that contains the file.
Appendix 2. Intronic and untranslated region sequence variants found in
SKI.
All non-coding sequence variants observed for SKI are
reported in this table. ‘- -‘ denotes lack of sequence data for
that corresponding sample. To access the data, click or select
the words “Appendix 2.” This will initiate the download of a
compressed (pdf) archive that contains the file.
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